CA3190148A1 - Compositions and methods related to ebolavirus vaccines - Google Patents

Compositions and methods related to ebolavirus vaccines

Info

Publication number
CA3190148A1
CA3190148A1 CA3190148A CA3190148A CA3190148A1 CA 3190148 A1 CA3190148 A1 CA 3190148A1 CA 3190148 A CA3190148 A CA 3190148A CA 3190148 A CA3190148 A CA 3190148A CA 3190148 A1 CA3190148 A1 CA 3190148A1
Authority
CA
Canada
Prior art keywords
ebolavirus
engineered
protein
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190148A
Other languages
English (en)
French (fr)
Inventor
Linling HE
Jiang Zhu
Anshul Chaudhary
Ian Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA3190148A1 publication Critical patent/CA3190148A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3190148A 2020-08-10 2021-08-09 Compositions and methods related to ebolavirus vaccines Pending CA3190148A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063530P 2020-08-10 2020-08-10
US63/063,530 2020-08-10
PCT/US2021/045178 WO2022035739A2 (en) 2020-08-10 2021-08-09 Compositions and methods related to ebola virusvaccines

Publications (1)

Publication Number Publication Date
CA3190148A1 true CA3190148A1 (en) 2022-02-17

Family

ID=80114705

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190148A Pending CA3190148A1 (en) 2020-08-10 2021-08-09 Compositions and methods related to ebolavirus vaccines

Country Status (10)

Country Link
US (2) US11305004B2 (https=)
EP (1) EP4192500A4 (https=)
JP (1) JP7631502B2 (https=)
CN (1) CN116472278A (https=)
AU (1) AU2021324954A1 (https=)
CA (1) CA3190148A1 (https=)
IL (1) IL300527A (https=)
MX (1) MX2023001433A (https=)
WO (1) WO2022035739A2 (https=)
ZA (1) ZA202301221B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130061A1 (en) * 2022-12-16 2024-06-20 Cz Biohub Sf, Llc Immunogenic ebolavirus fusion proteins and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
GB201502209D0 (en) * 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
WO2016145385A2 (en) 2015-03-11 2016-09-15 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
US11135280B2 (en) * 2016-03-28 2021-10-05 Integrated Biotherapeutics, Inc. Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
KR20260047644A (ko) * 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
CN107034225B (zh) * 2017-05-04 2020-01-17 中国人民解放军军事医学科学院生物工程研究所 制备埃博拉病毒糖蛋白与基质蛋白融合突变体的方法
WO2019241483A1 (en) 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
CA3107083A1 (en) * 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers

Also Published As

Publication number Publication date
WO2022035739A3 (en) 2022-03-24
JP7631502B2 (ja) 2025-02-18
US11872277B2 (en) 2024-01-16
US11305004B2 (en) 2022-04-19
US20220040286A1 (en) 2022-02-10
US20220305109A1 (en) 2022-09-29
CN116472278A (zh) 2023-07-21
IL300527A (en) 2023-04-01
ZA202301221B (en) 2024-05-30
MX2023001433A (es) 2023-03-06
EP4192500A4 (en) 2025-01-01
WO2022035739A2 (en) 2022-02-17
EP4192500A2 (en) 2023-06-14
AU2021324954A1 (en) 2023-02-23
JP2023537518A (ja) 2023-09-01

Similar Documents

Publication Publication Date Title
US12447206B2 (en) Nanoparticle vaccines with novel structural components
CN112538105A (zh) 稳定的冠状病毒刺突(s)蛋白抗原和相关疫苗
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
US20230034467A1 (en) Engineered HCV E2 Immunogens and Related Vaccine Compositions
US11872277B2 (en) Compositions and methods related to ebolavirus vaccines
JP2023537518A5 (https=)
EA050680B1 (ru) Композиции и способы, связанные с вакцинами против эболавируса
WO2025144636A1 (en) ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
EA047661B1 (ru) Стабилизированные иммуногены коронавирусного шиповидного белка (s) и связанные вакцины
EA046652B1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240705

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127